Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Camp4 Therapeutics (CAMP) Asset Writedowns and Impairment (2025)

Camp4 Therapeutics' Asset Writedowns and Impairment history spans 1 years, with the latest figure at $494000.0 for Q3 2025.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $494000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $494000.0, a N/A change, with the full-year FY2025 number at $494000.0, changed N/A from a year prior.
Asset Writedowns and Impairment hit $494000.0 in Q3 2025 for Camp4 Therapeutics.
Over the last five years, Asset Writedowns and Impairment for CAMP hit a ceiling of $494000.0 in Q3 2025 and a floor of $494000.0 in Q3 2025.